Logotype for Anika Therapeutics Inc

Anika Therapeutics (ANIK) investor relations material

Anika Therapeutics Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Anika Therapeutics Inc
Q3 2025 earnings summary5 Nov, 2025

Executive summary

  • Q3 2025 revenue was $27.8 million, down 6% year-over-year, with Commercial Channel revenue up 22% and OEM Channel revenue down 20% due to pricing pressure and lower volumes.

  • Integrity Implant System and Regenerative Solutions drove strong growth, with Integrity procedures up for the sixth consecutive quarter and Regenerative Solutions up 25% year-over-year.

  • Hyalofast PMA was submitted to the FDA, supported by positive Phase III data, and Cingal surpassed one million injections globally.

  • Operating expenses decreased 3% year-over-year, with SG&A down 12% and adjusted EBITDA at $0.9 million; operating cash flow was $6.9 million.

  • Strategic review concluded, with a $15 million share repurchase program initiated and focus on OA Pain Management and Regenerative Solutions.

Financial highlights

  • Q3 2025 revenue was $27.8 million, down from $29.6 million in Q3 2024, mainly due to a 20% drop in OEM revenue.

  • Commercial Channel revenue reached $12 million, up 22% year-over-year, driven by Regenerative Solutions and international OA Pain sales.

  • Gross margin was 56%, down from 66% in Q3 2024 but up 5 points sequentially from Q2.

  • Adjusted EBITDA was $0.9 million, down from $4.5 million in Q3 2024 but improved $1 million sequentially.

  • Cash balance at quarter-end was $58 million, with operating cash flow of $6.9 million.

Outlook and guidance

  • Fiscal 2025 guidance reaffirmed: Commercial Channel revenue expected at $47–$49.5 million (up 12–18% YoY), OEM Channel at $62–$65 million (down 16–20% YoY).

  • Adjusted EBITDA guidance for 2025 is flat to modestly lower, at -3% to +3%.

  • Strategic focus on OA Pain Management, mid-term Hyalofast launch, and long-term Cingal launch.

  • No need to raise capital; focus remains on positive operating cash flow and reinvestment in the business.

  • J&J MedTech extended Monovisc U.S. marketing agreement through 2031; Orthovisc through 2028.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Anika Therapeutics earnings date

Logotype for Anika Therapeutics Inc
Q4 20259 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Anika Therapeutics earnings date

Logotype for Anika Therapeutics Inc
Q4 20259 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Anika Therapeutics Inc. is a medical technology company focused on developing, manufacturing, and commercializing products for joint health and orthopedic applications. The company's offerings include therapeutic solutions for pain management, joint preservation, and tissue repair, utilizing proprietary hyaluronic acid-based technology and other advanced biomaterials. Anika serves healthcare providers, including orthopedic surgeons and clinicians, with a portfolio that addresses conditions such as osteoarthritis and soft tissue injuries. The company is headquartered in Bedford, Massachusetts, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage